Table of Content


Introduction
Global Markets Direct Report Coverage
Mucopolysaccharidosis I - Overview
Mucopolysaccharidosis I - Therapeutics Development
Mucopolysaccharidosis I - Therapeutics Assessment
Mucopolysaccharidosis I - Companies Involved in Therapeutics Development
Mucopolysaccharidosis I - Drug Profiles
Mucopolysaccharidosis I - Dormant Projects
Mucopolysaccharidosis I - Discontinued Products
Mucopolysaccharidosis I - Product Development Milestones
Appendix



List of Figures

List of Figures
Number of Products under Development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by ArmaGen Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by BioStrategies LC, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Denali Therapeutics Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by EdiGene Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Eloxx Pharmaceuticals Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Gain Therapeutics Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Immusoft Corp, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by JCR Pharmaceuticals Co Ltd, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Jupiter Neurosciences Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Orchard Therapeutics Plc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Ossianix Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Paradigm Biopharmaceuticals Ltd, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Rain Bio Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by RegenxBio Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by ReqMed Co Ltd, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Sigilon Therapeutics Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Tega Therapeutics Inc, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Dormant Projects, 2021
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Discontinued Products, 2021